1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
REGULATORY
Japan OKs Honebuto Paper with No Mention of Drug Pricing; Stable Supply, Innovation, Biosimilar Promotion Spelled Out
Japan’s Cabinet approved the 2022 Basic Policy for Economic and Fiscal Management and Reform (honebuto) on June 7, which included no mention of pharmaceutical pricing but called for ensuring the quality and stable supply of medicines and boosting drug discovery…
To read the full story
Related Article
- Japan Govt to Set Biosimilar Target by March 2023: Honebuto Draft
June 6, 2022
- Honebuto Draft Fails to Clear LDP, Renewed Discussions Set for June 3
June 2, 2022
- Govt’s Draft Grand Design for New Capitalism Vows to Spur Biotechnology Innovation
June 1, 2022
- Honebuto Draft Makes No Mention of Off-Year Re-Pricing or Buffer Zone, Calls for Stronger Drug Discovery Capabilities
June 1, 2022
- Deregulation Panel Urges Better Data Infrastructure, DCT Promotion to Boost Drug Discovery in Japan
May 30, 2022
REGULATORY
- LDP Lawmakers Urge Generic Industry to Ramp Up Production
February 28, 2025
- J&J’s Lazcluze, Genmab’s Tivdak and More Drugs in Line for Japan Approval
February 28, 2025
- LDP, Komeito, Ishin Agree to Set Up Consultive Body for Social Security Reform
February 26, 2025
- Coordinate Patent Issues with Originators before Listing: MHLW to Generic Firms
February 26, 2025
- Care Avoidance from Copay Cap Hike Likely to Result in 195 Billion Yen Cost Reduction
February 25, 2025
In late January, a bill to amend the Pharmaceuticals and Medical Devices Act cleared key legislation review processes by the…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…